FDA Diagnostics Chief Predicts Multiple Warning Letters For ASR Violations
This article was originally published in The Gray Sheet
Executive Summary
FDA expects to send out multiple warning letters to firms for illegally selling diagnostic products as 510(k)-exempt analyte specific reagents instead of as test kits, which are more heavily regulated
You may also be interested in...
FDA Says Final CLIA Waiver Guidance Eases Burdens; Industry Isn’t Satisfied
Final guidelines to companies developing point-of-care diagnostic tests for use in less sophisticated laboratories offer more leeway in clinical trial design than FDA initially proposed
Test Makers Have One Year To Comply With New ASR Guidelines
Diagnostic test makers will have until September 2008 to comply with newly clarified FDA policies for analyte specific reagents
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.